Clinical Trials

IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results

IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.

Kura Oncology reports positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).

AstraZeneca’s COPD drug Duaklir meets primary endpoints in phase III Amplify trial

AstraZeneca’s Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) has met its primary endpoints in the Phase III Amplify trial of patients with chronic obstructive pulmonary disease (COPD).

Cancer Research UK launches clinical trial to test new cancer drug

Cancer Research UK has launched a clinical study to evaluate a new cancer drug in patients with advanced solid tumours in four centres across the UK through its Centre for Drug Development.

Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial

Ultragenyx Pharmaceutical’s phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) failed to meet primary endpoint of showing a statistically significant difference in the upper extremity muscle strength composite score compared to placebo.

ViraCyte announces positive phase 2 trial results

ViraCyte has announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M.

Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib

Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer.

Ovid Therapeutics recruits first patient in phase 1b/2a trial of TAK-935/OV935 in adults with rare epilepsies

Ovid Therapeutics announced it has randomized the first patient in its Phase 1b/2a clinical trial of TAK-935, also known as OV935, in collaboration with Takeda Pharmaceutical Company Limited.

US DOD to commence new trial with Pluristem’s PLX-R18 cell therapy against ARS

Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).